====== Temozolomide Indications ======

First therapeutic report of [[temozolomide]] to treat human [[glioma]]s
((Friedman HS, McLendon RE, Kerby T, et al. [[DNA mismatch repair]]
and O6-alkylguanine-DNA alkyltransferase analysis and response to
Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998;16:
3851–7)) in [[1999]].
----
[[Methylation]] of the [[gene]]'s promoter may play a significant role in carcinogenesis. In patients with [[glioblastoma multiforme]], the methylation state of the [[MGMT]] gene determined whether tumor cells would be responsive to [[temozolomide]]; if the promoter was methylated, temozolomide was more effective.
----

Treatment with temozolomide following surgical debulking extends survival rate compared to [[radiotherapy]] and debulking alone. However, virtually all glioblastoma patients experience disease progression within 7 to 10 months. Although many salvage treatments, including bevacizumab, rechallenge with temozolomide, and other alkylating agents, have been evaluated, none of these clearly improves survival
((Sharpe MA, Livingston AD, Gist TL, Ghosh P, Han J, Baskin DS. Successful
Treatment of Intracranial Glioblastoma Xenografts With a Monoamine Oxidase
B-Activated Pro-Drug. EBioMedicine. 2015 Aug 8;2(9):1122-32. doi:
10.1016/j.ebiom.2015.08.013. PubMed PMID: 26501110; PubMed Central PMCID:
PMC4588367.
)).


===== Glioblastoma =====

see [[Temozolomide for glioblastoma]].

===== low-grade glioma  =====

see [[Temozolomide for low-grade glioma ]].

===== Central neurocytoma =====

see [[Temozolomide for central neurocytoma]].

===== Temozolomide for Invasive pituitary neuroendocrine tumor =====
[[Temozolomide for Invasive pituitary neuroendocrine tumor]].